What DeepSeek’s Launch Means For The Human-in-the-Loop AI Market
DeepSeek’s AI model challenges traditional HITL approaches, using synthetic data and expert input to reshape AI training and ...
U.S. MANUFACTURING PICKED UP IN JANUARY DRIVEN BY GROWING DEMAND: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
The GEP Global Supply Chain Volatility Index — a leading indicator tracking demand conditions, shortages, transportation ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Arvinas Holding Company (ARVN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biohaven Ltd. (BHVN – Research Report), ...
Diginomica7h
Confluent Q4 2024 earnings beat expectations as data streaming vendor expands partnership with Databricks
Using Apache Iceberg with Tableflow, Confluent Cloud automatically performs the required data preprocessing and ingested into ...
On The AI Playing Field, A Robust Data Strategy Is The MVP
Above all, data must be connected to be usable. Entity Resolution (ER) plays a crucial role in connecting disparate data. ER ...
AutoNation, Inc. (AN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 11, 2025 9:00 AM ETCompany ParticipantsDerek Fiebig - Vice President, ...
Why Earnings Season Matters
Imagine that, once every few months, you must release information detailing your current financial standing. That's just a ...
CSL (CMXHF) Gets a Buy from Morgans
In a report released today, Derek Jellinek from Morgans maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...
Commonwealth Bank delivers bumper $5.1b profit
Commonwealth Bank has hiked its dividend after delivering a $5.1 billion first-half cash net profit, up 2 per cent from a ...
Commonwealth Bank records a mega $5.1billion profit
Commonwealth Bank has hiked its dividend after delivering a $5.1 billion first half cash net profit, up two per cent from a ...
Arvinas anticipates Phase 3 topline results for vepdegestrant in Q1 2025 with commercial preparations underway
Q4 2024 Management View CEO John Houston emphasized that Arvinas is nearing key milestones, including the first Phase 3 topline data for vepdegestrant (vepdeg) from the VERITAC-2 trial expected in Q1 ...